Forbes -
11 Mar 2021 13:30

Roche's ADR looks attractive at current levels of $41, as it is up only 17% from the levels it was at on March 23, 2020, when broader markets made a bottom due to the spread of Covid-19. This marks a significant underperformance compared to the S&P which has moved 73% since its March 2020 lows...
Share this Article
Comment on this Article
Please to comment